ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för arachidonyl-2'-chloroethylamide. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

22 träffar

Bibliografisk träff 2022-02-21

Dual action of the cannabinoid receptor 1 ligand arachidonyl-2'-chloroethylamide on calcitonin gene-related peptide release.

Christiansen IM, Edvinsson JCA, Reducha PV, Edvinsson L, Haanes KA.

J Headache Pain · research-article; journal article · DOI 10.1186/s10194-022-01399-8

Bibliografisk träff 2021-06-04

Chronic unpredictable stress during adolescence protects against adult traumatic brain injury-induced affective and cognitive deficits.

de la Tremblaye PB, Wellcome JL, Wiley K, Lomahan CA, Moschonas EH, Cheng JP, Bondi CO, Kline AE.

Brain Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.brainres.2021.147544

Bibliografisk träff 2020-11-19

AM251, a cannabinoid receptor 1 antagonist, prevents human fibroblasts differentiation and collagen deposition induced by TGF-β - An in vitro study.

Correia-Sá IB, Carvalho CM, Serrão PV, Machado VA, Carvalho SO, Marques M, Vieira-Coelho MA.

Eur J Pharmacol · journal article · DOI 10.1016/j.ejphar.2020.173738

Bibliografisk träff 2020-10-12

Cannabinoid CB1 receptor agonist ACEA alleviates brain ischemia/reperfusion injury via CB1-Drp1 pathway.

Yang S, Hu B, Wang Z, Zhang C, Jiao H, Mao Z, Wei L, Jia J, Zhao J.

Cell Death Discov · research-article; journal article · DOI 10.1038/s41420-020-00338-3

Bibliografisk träff 2020-05-12

Arachidonyl-2'-chloroethylamide (ACEA), a synthetic agonist of cannabinoid receptor, increases CB<sub>1</sub>R gene expression and reduces dyskinesias in a rat model of Parkinson's disease.

Leija-Salazar M, Bermúdez de León M, González-Horta A, González-Hernández B.

Pharmacol Biochem Behav · research support, non-u.s. gov't; journal article · DOI 10.1016/j.pbb.2020.172950

Bibliografisk träff 2019-01-03

Cannabinoid Receptor Type 1 Agonist ACEA Improves Cognitive Deficit on STZ-Induced Neurotoxicity Through Apoptosis Pathway and NO Modulation.

Crunfli F, Vrechi TA, Costa AP, Torrão AS.

Neurotox Res · journal article · DOI 10.1007/s12640-018-9991-2

Bibliografisk träff 2018-12-12

Levetiracetam combined with ACEA, highly selective cannabinoid CB1 receptor agonist changes neurogenesis in mouse brain.

Zagaja M, Haratym-Maj A, Szewczyk A, Rola R, Maj M, Łuszczki JJ, Andres-Mach M.

Neurosci Lett · research support, non-u.s. gov't; journal article · DOI 10.1016/j.neulet.2018.12.016

Bibliografisk träff 2017-08-31

Effects of arachidonyl-2'-chloroethylamide (ACEA) on the protective action of various antiepileptic drugs in the 6-Hz corneal stimulation model in mice.

Luszczki JJ, Patrzylas P, Zagaja M, Andres-Mach M, Zaluska K, Kondrat-Wrobel MW, Szpringer M, Chmielewski J, Florek-Luszczki M.

PLoS One · research-article; journal article · DOI 10.1371/journal.pone.0183873

Bibliografisk träff 2017-04-25

A Long-Term Treatment with Arachidonyl-2'-Chloroethylamide Combined with Valproate Increases Neurogenesis in a Mouse Pilocarpine Model of Epilepsy.

Andres-Mach M, Zagaja M, Haratym-Maj A, Rola R, Maj M, Haratym J, Dudra-Jastrzębska M, Łuszczki JJ.

Int J Mol Sci · research-article; journal article · DOI 10.3390/ijms18050900

Bibliografisk träff 2016-09-20

Pharmacokinetic-pharmacodynamic influence of N-palmitoylethanolamine, arachidonyl-2'-chloroethylamide and WIN 55,212-2 on the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice.

Citraro R, Russo E, Leo A, Russo R, Avagliano C, Navarra M, Calignano A, De Sarro G.

Eur J Pharmacol · journal article · DOI 10.1016/j.ejphar.2016.09.029

Bibliografisk träff 2016-01-28

Arachidonyl-2-Chloroethylamide Alleviates Cerebral Ischemia Injury Through Glycogen Synthase Kinase-3β-Mediated Mitochondrial Biogenesis and Functional Improvement.

Bai F, Guo F, Jiang T, Wei H, Zhou H, Yin H, Zhong H, Xiong L, Wang Q.

Mol Neurobiol · research support, non-u.s. gov't; journal article · DOI 10.1007/s12035-016-9731-7

Bibliografisk träff 2015-05-12

Influence of arachidonyl-2'-chloroethylamide, a selective cannabinoid CB1 receptor agonist, on the anticonvulsant and acute side-effect potentials of clobazam, lacosamide, and pregabalin in the maximal electroshock-induced seizure model and chimney test in mice.

Florek-Luszczki M, Zagaja M, Luszczki JJ.

Fundam Clin Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1111/fcp.12123

Bibliografisk träff 2015-04-14

CB1 cannabinoid receptor agonist inhibits matrix metalloproteinase activity in spinal cord injury: A possible mechanism of improved recovery.

Hong J, Nandiwada V, Jones V, Lu M, Warner DS, Mukhopadhyay S, Sheng H.

Neurosci Lett · journal article · DOI 10.1016/j.neulet.2015.04.016

Bibliografisk träff 2009-09-13

Effect of arachidonyl-2'-chloroethylamide, a selective cannabinoid CB1 receptor agonist, on the protective action of the various antiepileptic drugs in the mouse maximal electroshock-induced seizure model.

Luszczki JJ, Czuczwar P, Cioczek-Czuczwar A, Dudra-Jastrzebska M, Andres-Mach M, Czuczwar SJ.

Prog Neuropsychopharmacol Biol Psychiatry · research support, non-u.s. gov't; journal article · DOI 10.1016/j.pnpbp.2009.09.005

Bibliografisk träff 2008-04-01

Additive interaction of the cannabinoid receptor I agonist arachidonyl-2-chloroethylamide with etomidate in a sedation model in mice.

Meybohm P, Brand PA, Ufer M, Thiemann F, Steinfath M, Paris A, Scholz J, Bein B.

Anesthesiology · comparative study; journal article · DOI 10.1097/aln.0b013e318167aef7

Bibliografisk träff 2006-07-27

Arachidonyl-2'-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model.

Luszczki JJ, Czuczwar P, Cioczek-Czuczwar A, Czuczwar SJ.

Eur J Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejphar.2006.07.037

Bibliografisk träff 2006-04-01

ACEA (arachidonyl-2-chloroethylamide), the selective cannabinoid CB1 receptor agonist, protects against aspirin-induced gastric ulceration.

Rutkowska M, Fereniec-Gołtbiewska L.

Pharmazie · journal article

Bibliografisk träff 2004-07-26

The cannabinomimetic arachidonyl-2-chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints.

Baker CL, McDougall JJ.

Br J Pharmacol · comparative study; research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/sj.bjp.0705902

Bibliografisk träff 2004-03-08

Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide.

Price TJ, Patwardhan A, Akopian AN, Hargreaves KM, Flores CM.

Br J Pharmacol · research support, u.s. gov't, p.h.s.; research-article; journal article · DOI 10.1038/sj.bjp.0705711

Bibliografisk träff 2004-03-01

Antidepressant--like properties of ACEA (arachidonyl-2-chloroethylamide), the selective agonist of CB1 receptors.

Rutkowska M, Jachimczuk O.

Acta Pol Pharm · comparative study; journal article

Bibliografisk träff 2002-07-01

The cannabinoids R(-)-7-hydroxy-delta-6-tetra-hydrocannabinol-dimethylheptyl (HU-210), 2-O-arachidonoylglycerylether (HU-310) and arachidonyl-2-chloroethylamide (ACEA) increase isoflurane provoked sleep duration by activation of cannabinoids 1 (CB1)-receptors in mice.

Schuster J, Ates M, Brune K, Gühring H.

Neurosci Lett · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1016/s0304-3940(02)00302-6

Bibliografisk träff 1999-06-01

Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1).

Hillard CJ, Manna S, Greenberg MJ, DiCamelli R, Ross RA, Stevenson LA, Murphy V, Pertwee RG, Campbell WB.

J Pharmacol Exp Ther · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article · DOI 10.1016/s0022-3565(24)38289-8